Most Read Articles
Audrey Abella, 27 Nov 2020
Use of the potent and selective PPARδ* agonist seladelpar led to improvements in histologic responses and liver chemistry in patients with biopsy-confirmed nonalcoholic steatohepatitis (NASH), a phase II study has shown.
Roshini Claire Anthony, 6 days ago

The efficacy of lanifibranor in reducing histological markers of non-alcoholic steatohepatitis (NASH) is comparable in patients with and without type 2 diabetes (T2D), according to the phase IIb NATIVE study presented as a poster at AASLD 2020.

Tristan Manalac, 17 Nov 2020
Adding dapagliflozin (DAPA) and saxaglipitin (SAXA) to routine metformin treatment in type 2 diabetes (T2D) leads to a decrease in liver fat and adipose tissue, according to a new study presented at The Liver Meeting Digital Experience by the American Association for the Study of Liver Diseases (AASLD 2020).
Jairia Dela Cruz, 18 Nov 2020
The small molecule fatty acid synthase inhibitor TVB-2640 boasts a win in addressing the three key drivers of nonalcoholic steatohepatitis (NASH)—namely liver fat, fibrosis, and inflammation—in the phase II FASCINATE-1 trial presented during The Liver Meeting Digital Experience of the American Association for the Study of Liver Diseases (AASLD).

Elevated testosterone a red flag for NASH progression in young women

28 Oct 2020

High testosterone levels carry a twofold increased risk of progression to nonalcoholic steatohepatitis (NASH) and fibrosis, as well as a higher likelihood of abdominal obesity, in young women with nonalcoholic fatty liver disease (NAFLD), a study has found.

The study involved 207 premenopausal women (median age, 35 years) with NAFLD. Most of them had abdominal adiposity (93 percent), dyslipidaemia (96 percent), and were obese (81 percent). Meanwhile, 32 percent had type 2 diabetes, 31 percent had hypertension, and 21 percent had self-reported polycystic ovary syndrome.

At baseline, median free testosterone (free T) was 3.6 pg/mL, while median total testosterone level was 210 pg/mL. The levels decreased with increasing age (ptrend<0.04). Sixty-nine percent of women had borderline or definite NASH, and 67 percent had evidence of fibrosis. Advanced fibrosis (stages 3–4) was present in 15 percent of the women overall and in 20 percent of those with NASH.

In multivariable regression models, high free T levels were associated with NAFLD severity among younger women (p<0.02). In the youngest age quartile (n=52; 22–27 years), elevated free T independently predicted the following outcomes: NASH (odds ratio [OR], 2.3, 95 percent confidence interval [CI], 1.2–4.4), NASH fibrosis (OR, 2.1, 95 percent CI, 1.1–3.8), and higher fibrosis stage (OR, 1.9, 95 percent CI, 1.1–3.4; p≤0.02 for all).

Furthermore, in the youngest age quartile, the proportion of women with NASH or NASH fibrosis rose steadily from 27 percent to >80 percent with higher free T quartiles (p<0.01). Free T was also associated with abdominal obesity in the overall population (OR, 2.2, 95 percent CI, 1.2–4.1; p=0.015).

The findings indicate that testosterone potentially represents an early risk factor for NASH progression in young women, prior to their onset of more dominant, age-related metabolic risk factors.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Hepatology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Audrey Abella, 27 Nov 2020
Use of the potent and selective PPARδ* agonist seladelpar led to improvements in histologic responses and liver chemistry in patients with biopsy-confirmed nonalcoholic steatohepatitis (NASH), a phase II study has shown.
Roshini Claire Anthony, 6 days ago

The efficacy of lanifibranor in reducing histological markers of non-alcoholic steatohepatitis (NASH) is comparable in patients with and without type 2 diabetes (T2D), according to the phase IIb NATIVE study presented as a poster at AASLD 2020.

Tristan Manalac, 17 Nov 2020
Adding dapagliflozin (DAPA) and saxaglipitin (SAXA) to routine metformin treatment in type 2 diabetes (T2D) leads to a decrease in liver fat and adipose tissue, according to a new study presented at The Liver Meeting Digital Experience by the American Association for the Study of Liver Diseases (AASLD 2020).
Jairia Dela Cruz, 18 Nov 2020
The small molecule fatty acid synthase inhibitor TVB-2640 boasts a win in addressing the three key drivers of nonalcoholic steatohepatitis (NASH)—namely liver fat, fibrosis, and inflammation—in the phase II FASCINATE-1 trial presented during The Liver Meeting Digital Experience of the American Association for the Study of Liver Diseases (AASLD).